Xarelto (rivaroxaban) is a blood thinner prescribed to treat or lower the risk of blood clots. Its most common side effect is bleeding, which can range from mild bruising to serious internal bleeding ...
Hendrickson used its press conference at the Technology & Maintenance Council’s 2026 Annual Meeting to introduce a new connected trailer technology platform. The new system is designed to give fleets ...
Hendrickson unveiled its Watchman wheel-end sensor system March 17 at TMC 2026. Watchman delivers tire pressure and wheel-end temperature data and generates alerts for leaks and low-pressure ...
Xarelto (rivaroxaban) may increase the risk of bleeding, especially when combined with alcohol, nonsteroidal anti-inflammatory drugs (NSAIDs), antiplatelet drugs, other blood thinners, and ...
TidalHealth Peninsula Regional recently performed its 700th WATCHMAN procedure, marking a significant milestone for the medical center, according to a community announcement. The WATCHMAN procedure is ...
The National Institutes of Health (NIH) halted a treatment arm of Bayer and Johnson & Johnson’s Xarelto (rivaroxaban) in a phase 3 stroke prevention trial after an independent committee flagged safety ...
Xarelto (rivaroxaban) and Eliquis (apixaban) are prescribed to prevent or treat blood clots in adults. Both Xarelto and Eliquis also have approved uses for children. Both drugs are also used to lower ...
In this episode of Version History: how Sony put a screen in your pocket, and changed the way we watched forever. In this episode of Version History: how Sony put a screen in your pocket, and changed ...
Rivaroxaban for oral suspension, 1 mg/ml (RLD Xarelto) had a market value of roughly $11 million, per IQVIA July 2025 data. Lupin has received approval from the Food and Drug Administration for ...
BATON ROUGE, La. (WAFB) - Atrial Fibrillation, or AFib is the leading cause of stroke. The American Heart Association says five million Americans currently have AFib, with an additional 12 million ...
More special care is needed when using the Watchman access systems used to deliver transcatheter left atrial appendage (LAA) closure devices due to a risk for air embolisms, according to an FDA alert.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results